Ivantis Gets $25M More

Irvine-based Ivantis, which is developing medical devices to treat glaucoma, has raised $25M more in its Series B funding, the company said this morning. The company said the new funding increases the round to a total of $71M in funding. The funding came from Foresite Capital, along with New Enterprise Associates (NEA), Delphi Ventures, Ascension Ventures, Vertex Ventures, GBS Ventures, EDBI, and MemorialCare Innovation Fund. Ivantis is developing a microstent device which is aimed at lowering eye pressure for glaucoma patients. The company said the new funds go towards clinical trials, and will take the company through U.S. approvals. Ivantis is led by Dave Van Meter. More information »